U.S. Early Toxicity Testing Market is expected to reach USD 4.14 billion by 2030
Robust healthcare infrastructure and cardiovascular disease prevalence in U.S. region is driving up demand for the U.S. early toxicity testing market during the forecast period.
U.S. Early Toxicity Testing Market was valued at USD 2.42 billion in 2022, and is predicted to reach USD 4.14 billion by 2030, with a CAGR of 6.02% from 2023 to 2030, according to new research by Next Move Strategy Consulting.
The expansion of the early toxicity testing market can be attributed to the strong healthcare infrastructure, substantial research and development investments, and a rising need for top-notch pharmaceutical products within the United States.
For instance, according to the Centers for Medicare & Medicaid Services, the national healthcare expenditure reached 4.3 trillion in 2021 in the United States. In addition, the market is being driven by rise in prevalence of heart diseases, which is a leading cause of death in the U.S. and has been on the rise in recent years. For instance, according to the Centers for Disease Control and Prevention (CDC), around 697,000 Americans died from heart disease in 2020, which is approximately 1 in every 5 deaths.
However, stringent regulations set by regulatory bodies such as the US FDA and the EMA require extensive and rigorous testing for drug development and safety, which can be time-consuming and expensive and restrain growth of the market. The complexity and cost of complying with these regulations can pose a significant challenge for small and medium-sized companies that may not have the resources to carry out extensive testing. As a result, some companies may choose to delay or abandon drug development projects, which can limit demand for early toxicity testing services.
On the other hand, introduction of new technologies such as in-vitro modelling using 3D cell culture is expected to provide new lucrative opportunities for the early toxicity testing market during the forecast period. Use of 3D cell cultures can better mimic complexity of tissues and organs, providing more accurate and reliable results for toxicity testing. Traditional 2D cell culture models are limited in their ability to mimic complexity of human tissues and organs, often leading to inaccurate and unreliable results in toxicity testing.
Furthermore, use of 3D cell culture models can better mimic structural and functional complexity of tissues and organs, providing more accurate and reliable results for toxicity testing. 3D cell cultures allow growth and interaction of multiple cell types, creating a microenvironment that more closely resembles human tissues and organs. This can better predict toxic effects of drugs and chemicals in the human body, reducing the risk of adverse effects in clinical trials. Hence, such factors propel the ETT market growth.
Request for a sample here: https://www.nextmsc.com/us-early-toxicity-testing-market/request-sample
According to the report, leading players in the U.S. early toxicity testing market include Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG.
Key Insights from the U.S. Early Toxicity Testing Market Report:
The information related to key drivers, restraints, and opportunities and their impact on the U.S. early toxicity testing market is provided in the report.
The value chain analysis in the market study provides a clear picture of the roles of each stakeholder.
The market share of players in the U.S. early toxicity testing market is provided in the report along with their competitive analysis.